Different responsiveness of normal and leukemic hemopoietic cells to esorubicin.
The effect of different Esorubicin concentrations (10(-7) M to 10(-10) M) has been tested on the in vitro growth of human normal hemopoietic progenitor cells and of three leukemic cell lines (K562, U 937, HL60). The highest drug concentration completely abolished both normal and leukemic proliferation. Lower doses of Esorubicin failed to induce any morphological or phenotypic differentiation of leukemic cell lines. A 24h pretreatment of the cells with 10(-9) M Esorubicin enhanced the in vitro proliferation of normal early myeloid progenitor cells, whereas it did not affect leukemic, myelomonocytic cell proliferation.
Bagnara
G P
GP
Centro Interdipartimentale di Ricerche sul Cancro Giorgio Prodi, Bologna, Italy.
Rocchi
P
P
Zauli
G
G
Vitale
L
L
Licia
G
G
Damiano
R
R
Paolucci
G
G
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002478:Cells, Cultured; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000494:pharmacology; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D007938:Leukemia; D012016:Reference Values
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin; C030851:esorubicin